While clinical evidence 52,53 has indicated a possible elevated risk, causality has not been established
Therefore, individual treatment results may vary
In practice, microdoses are usually a fraction of the standard starting dose (for example, 0.125 mg or 0.25 mg of semaglutide rather than 0.5 mg)
The evidence sitting under both brands Whatever logo is on the box, the pharmacology traces back to the compound class: GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, plus the GIP/GLP-1 dual agonist tirzepatide
Crucially, they trigger insulin release only when glucose is already present in the bloodstream, minimizing the risk of dangerous hypoglycemia seen with some older diabetes drugs
Adiponectin also decreases hepatic de novo glucose production and reduces free fatty acid levels in the liver (196), thereby mitigating hepatic steatosis, enhancing insulin sensitivity, and improving the circulating lipid profile ( Figure 1 Section E)
